Prognostic role of multiple abnormal genes in non-small-cell lung cancer

Table 1 Variables between patients who received chemotherapy or TKI therapy

Therapy type	Chemotherapy	TKI therapy	P value
Sex
Female	7 (8.2)	20 (23.5)	0.0021
Male	37 (43.5)	21 (23.7)
Age
Less than 50 yr	7 (8.2)	4 (4.7)	0.7334
50-70 yr	27 (31.8)	26 (30.6)
Greater than 70 yr	10 (11.8)	11 (12.9)
Smoking history
Ever	27 (31.7)	15 (17.6)	0.0302
Never	17 (20.0)	26 (30.6)
Tumor histology
LUAD	35 (41.1)	37 (43.5)	0.2317
LUSC & Others	9 (10.6)	4 (4.7)
Cancer stage
I and II	2 (2.4)	4 (4.7)	0.4227
III and IV	42 (49.4)	37 (43.5)
OS
< 12 mo	28 (32.9)	12 (14.1)	0.0022
≥ 12 mo	16 (18.8)	29 (34.1)

TKI: Tyrosine kinase inhibitor; LUAD: Lung adenocarcinoma; OS: Overall survival.